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Abstract
The ras proto-oncogene is one of the most frequently mutated genes in human cancer. However, given the prevalence of
activating mutations in Ras and its association with aggressive forms of cancer, attempts to therapeutically target aberrant
Ras signaling have been largely disappointing. This lack of progress highlights the deficiency in our understanding of
cellular pathways required for Ras-mediated tumorigenesis and suggests the importance of identifying new molecular
pathways associated with Ras-driven malignancies. Cdc42 is a Ras-related small GTPase that is known to play roles in
oncogenic processes such as cell growth, survival, invasion, and migration. A pan-dominant negative mutant
overexpression approach to suppress Cdc42 and related pathways has previously shown a requirement for Cdc42 in
Ras-induced anchorage-independent cell growth, however the lack of specificity of such approaches make it difficult to
determine if effects are directly related to changes in Cdc42 activity or other Rho family members. Therefore, in order to
directly and unambiguously address the role of Cdc42 in Ras-mediated transformation, tumor formation and maintenance,
we have developed a model of conditional cdc42 gene in Ras-transformed cells. Loss of Cdc42 drastically alters the cell
morphology and inhibits proliferation, cell cycle progression and tumorigenicity of Ras-transformed cells, while non-
transformed cells or c-Myc transformed cells are largely unaffected. The loss of Cdc42 in Ras-transformed cells results in
reduced Akt signaling, restoration of which could partially rescues the proliferation defects associated with Cdc42 loss.
Moreover, disruption of Cdc42 function in established tumors inhibited continued tumor growth. These studies implicate
Cdc42 in Ras-driven tumor growth and suggest that targeting Cdc42 is beneficial in Ras-mediated malignancies.
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Introduction
The ras proto-oncogene is mutated in approximately 30% of
human cancers, including three of the four most deadly cancers in
the United States: lung, colon and pancreatic cancers [1,2]. The
Ras protein functions as a central component of multiple
mitogenic signaling pathways and regulates a variety of cellular
processes including cell growth, differentiation and apoptosis. In
response to growth factor signaling, guanine nucleotide exchange
factors (GEFs) mediate the cycling of Ras from an inactive, GDP-
bound form to an active, GTP-bound form. It is in this GTP-
bound form that Ras can interact with a variety of effector
molecules, the best characterized of which are the Raf kinase and
Phosphatidylinositol 3-kinase (PI3K), to elicit various cellular
responses. Ras signaling is terminated by the activity of GTPase
activating proteins (GAPs), which accelerate the intrinsic GTPase
activity of Ras, returning it to its inactive, GDP-bound form [3].
Cancer-associated mutations in the ras gene result in both
a diminution of the intrinsic GTPase activity of the Ras protein
as well as an insensitivity to GAPs. Therefore, the consequence of
Ras mutation is a protein that remains perpetually and aberrantly
GTP bound, resulting in constitutively active signaling to
downstream effector molecules to promote cell growth and
survival associated with cellular transformation.
Given the frequency of Ras activation observed in human
cancers, extensive effort has been made to therapeutically target
aberrant Ras signaling. However, Ras itself has not been
considered a tractable target for small molecule interventions
and indirect targeting of Ras activities by farnesyl transferase
inhibitors failed to reach the clinic [2,4]. Major effort has now
focused on the targeting of Ras effector pathways such as the Raf-
MEK-ERK and PI3K-Akt pathways. Intriguingly, emerging
studies examining the molecular mechanisms of Ras-driven
transformation have begun to question the impact of the canonical
Ras effector pathway, i.e. Raf-MEK-ERK, for Ras-mediated
oncogenesis. High throughput RNAi screens designed to identify
synthetic lethal interactions in Ras-dependent, K-Ras mutant
cancer cells failed to identify genes within the MEK pathway as
necessary for cell growth and viability [5,6,7]. Cancers expressing
oncogenic Ras display varying degrees of sensitivity to MEK
inhibition with an overall low level of sensitivity to such inhibitors
when compared to cancers harboring BRaf mutations [8]. In
addition, a lack of sensitivity to MEK inhibition is consistent with
the observation that mutant Ras often does not drive aberrant
activation of ERK in cancer cells [9]. Combined, these studies
suggest that while signaling to ERK may be crucial for Ras
function in normal cells, this pathway may not be the only means
of Ras-mediated transformation in cancer cells. Moreover, these
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required for the transforming potential of Ras, as these endeavors
may identify other relevant targets for the treatment of cancers
driven by oncogenic Ras.
A number of studies have found that the Ras-related small
GTPase, Cdc42, becomes activated upon expression of oncogenic
Ras [10,11]. Like Ras, Cdc42 functions as a molecular switch,
cycling from an inactive, GDP-bound form to an active, GTP-
bound form in response to a variety of extracellular stimuli. Once
activated, Cdc42 can regulate cellular processes such as pro-
liferation, actin remodeling, vesicle trafficking and cell polarity
[12]. Furthermore, Cdc42 activity has been shown to impinge on
Ras-induced signaling pathways including the Raf-MEK-ERK
and PI3K-Akt pathways. For instance, while active Cdc42 can
bind the p85 subunit of PI3K leading to increased PI3K activity
[13], a Cdc42 effector kinase, PAK, may phosphorylate both Raf
and MEK to enhance signaling through ERK [14,15,16].
Additionally, studies utilizing a dominant-negative Cdc42 mutant
suggest that Cdc42 and/or related pathways may be important for
Ras-mediated transformation [17].
Here, we present data using a genetic model of Cdc42 loss,
which avoids specificity issues commonly associated with the
dominant-negative mutant approaches to inhibit Cdc42 function
[18,19], to demonstrate an essential role of Cdc42 in Ras
transformation and tumorigenesis. Building on previous bio-
chemical observations, we show that genetic deletion of cdc42 in
Ras-transformed cells results in a significant block in cell
proliferation and cell cycle progression, which is not observed in
non-transformed cells or cells transformed by the oncoprotein, c-
Myc. Further, cdc42 targeting results in a substantial reduction in
Figure 1. Cdc42 activity is increased upon Ras-mediated transformation. (a) Cell immortalization was achieved following retroviral
transduction of cdc42
f/f cells with a dominant-negative p53 (p53dd). Dominant-negative expression was determined by western blot for p53. (b)
Immortalized, cdc42
f/f cells were transformed through retroviral transduction with HRasV12. Transformed cells exhibit HRas overexpression and
increased active, GTP-bound HRas as determined by pull-down with the ras binding domain (RBD) of Raf1 fused to GST. (c) HRasV12 transformed cells
exhibit a significant increase in Cdc42 activity compared to non-transformed control cells. Pull-down assays were performed with GST-PAK1. The
graphed data represents densitometry quantification from three independent experiments.
doi:10.1371/journal.pone.0037317.g001
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established tumors, suggesting that Cdc42 activation by oncogenic
Ras is crucial for Ras-mediated tumorigenesis and tumor
maintenance. Finally, our results implicate Cdc42 as a potentially
useful therapeutic target in malignancies harboring activating Ras
mutation.
Results
Cdc42 is Activated upon Cell Transformation by HRasV12
Studies utilizing a dominant-negative approach to inhibit Cdc42
function in the context of HRasV12-driven cell transformation
have suggested that Cdc42 function could be important for the
transformation process induced upon aberrant Ras activation [17].
However, given the nonspecific nature of the dominant negative
mutant approach, how Cdc42 activity contributes to HRasV12-
mediated transformation and whether the targeting of Cdc42
could provide an opportunity for intervention to Ras-mediated
transformation have not been rigorously demonstrated. The
rationale that Cdc42 inhibition by dominant negative mutants
lacks specificity for Cdc42, potentially impinging on the function
of other Rho GTPases, is well documented [18,19]. Here, we have
developed a model of inducible cdc42 gene targeting in HRasV12-
transformed fibroblasts as well as non-transformed control cells.
Primary mouse embryonic fibroblasts (MEFs) were isolated from
cdc42
loxp/loxp mice, and subsequently immortalized following stable
transduction of a dominant negative p53 construct (p53dd)
(Figure 1a). Immortalized cells were then transformed through
viral transduction of the oncogene, HRasV12. Enhanced activa-
tion of the overexpressed oncogene was confirmed by a pull-down
assay with GST fused to the Ras binding domain (GST-RBD) of
Raf1, and a significant increase in Ras activity in HRasV12-
transformed cells relative to p53dd immortalized, non-transformed
controls was observed (Figure 1b). Furthermore, consistent with
previous reports, cellular transformation by HRasV12 resulted in
a significant increase in active Cdc42-GTP level relative to non-
transformed control cells (Figure 1c), thus associating active Cdc42
signaling with Ras-driven cell transformation.
Loss of Cdc42 Results in Dramatic Morphological
Changes in Ras-transformed Cells
Elevation of Cdc42 activity following overexpression of
HRasV12 suggests a role for Cdc42 signaling in cellular trans-
formation by oncogenic Ras. Therefore, to assess the consequence
of Cdc42 loss in both parental and Ras-transformed cells, the cells
were infected with either adenovirus expressing GFP-Cre to
induce recombination of the cdc42 locus or control adenovirus
expressing GFP alone. Cre recombinase expression in both
parental and HRasV12-expressing cells resulted in efficient
recombination of the cdc42 locus, as monitored by genomic PCR
(Figure 2a). As shown in Figure 2b, efficient cdc42 gene targeting
resulted in the loss of Cdc42 protein expression. Strikingly, while
Cdc42 depletion in non-transformed cells led to only modest
changes in cell morphology, as demonstrated by brightfield
microscopy and actin staining (Figure 2c), the loss of Cdc42 in
Ras-transformed cells resulted in a drastic morphological change
characterized by rounding of the cell body. However, in spite of
these dramatic changes in cell morphology, Cdc42-deficient Ras-
transformed cells remained viable as demonstrated by a lack of
TUNEL positive cells (Figure S1a). A slight increase in cleaved
Caspase 3 levels was observed (Figure S1b) when both adherent
and non-adherent cells were harvested for western blot analysis,
suggesting that subtle changes in cell viability observed upon
Cdc42 loss may be attributed to the reduction in cell adhesion.
Disruption of Effector Signaling upon Cdc42 Loss
Consistent with the morphological changes observed upon loss
of Cdc42 in Ras-transformed cells, reductions in both p-FAK and
p-MLC levels, two proteins whose activation is critical for focal
adhesion formation and maturation, were observed [20]. In non-
transformed cells in which no cell rounding was observed,
however, the phosphorylation status of these proteins remained
unchanged (Figure 2D). Additionally, oncogene transformed cells
are likely addicted to certain signaling pathways, therefore changes
in FAK and MLC activities specifically observed in Ras-
transformed cells may indicate that Ras-transformed cells are
dependent on Cdc42 signaling to activate FAK and MLC, while
non-transformed cells may be able to utilize alternative pathways
to modulate the activities of these proteins. The Cdc42 effector
protein, Par6, binds to Par3/aPKCs to form a complex associated
with tight junction formation at cell-cell contacts [21] and cell
polarization [22]. Additionally, this complex has been shown to
control polarity in migrating cells through the modulation of
GSK3b activity following phosphorylation at an inhibitory site,
serine 9 [23]. Both non-transformed and Ras-transformed cells
exhibited a reduction in phosphorlyation of GSK3b at this site,
suggesting disruption of the Par6/Par3/aPKC complex upon
Cdc42 loss and regardless of Ras activation status. Further,
activation of another established Cdc42 effector protein, PAK1,
showed a Ras-specific reduction upon Cdc42 loss. Therefore,
multiple pathways downstream of Cdc42 are affected upon Cdc42
deletion in Ras transformed cells.
Cdc42 Loss Inhibits Cell Growth and Transformation of
HRasV12-expressing Cells
The Rho family of small GTPases has been shown to be
required for G1/S transition [24]. However, previous studies
utilizing dominant negative Cdc42 mutants did not observe
a growth defect upon mutant expression in Ras-transformed cells
[17], and effects of Cdc42 on cell cycle progression appears to be
cell type specific as gene targeting of Cdc42 in hematopoietic stem
cells or neural progenitors resulted in an increased S-phase
transition [25,26]. Therefore, growth assays were carried out using
our inducible cdc42 gene targeting model to address these apparent
discrepancies. While non-transformed cells showed a modest
reduction in cell growth over time following Cdc42 deletion
(Figure 3a, upper panel), HRasV12-expressing cells exhibited
a dramatic and significant reduction in cell growth following
Cdc42 loss (Figure 3a, lower panel). To address the ability of
Cdc42 loss to inhibit Ras-mediated transformation, soft agar
colony formation assays were carried out to assess anchorage-
independent growth potential. Cdc42 deletion resulted in a signif-
icant reduction in colony formation (Figure 3b), suggesting that
Cdc42 function is crucial for Ras-mediated anchorage-indepen-
dent cell growth as well as growth in two dimensions. In contrast,
Cdc42 overexpression in Ras-transformed cells did not further
enhance cell growth, but did lead to enhanced soft agar colony
formation with colonies forming more rapidly and growing to
a larger size (Figure S2).
In an attempt to address the cellular mechanism of growth
reduction upon Cdc42 loss, BrdU assays were carried out to
investigate the consequence of Cdc42 loss on cell proliferation.
While no significant reduction in BrdU incorporation was
observed in parental cells, H-RasV12 expressing cells exhibited
a significant reduction in BrdU incorporation following Cdc42
deletion (Figure 3c). Furthermore, Ras-expressing cells showed
a reduction in Cyclin D1 and increase in p16
ink4a protein levels.
Thus, cdc42 deletion causes a G1 cell cycle arrest in Ras
transformed cells (Figure 3d).
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e37317Figure 2. Cdc42 deletion in HRasV12 transformed cells results in dramatic morphological changes and deregulation of Cdc42
effector pathways. (a) Recombination of the cdc42 locus following addition of Cre recombinase was monitored by genomic PCR detecting the loxp
allele. (b) Recombination of the cdc42 locus correlates with loss of Cdc42 protein expression as determined by western blot analysis. (c) Cultured
HRasV12 cells and non-transformed cells were visualized 4 days following cdc42 deletion by bright field microscopy (upper 4 panels). Cells were fixed
and stained with rhodamine-phalloidin and 4,6-diamidino-2-phenylindole (DAPI) to visualize actin structures. (d) Cell lysates from Ad-GFP-Cre and
control infected cells were immunoblotted for proteins involved in effector signaling downstream of activated Cdc42.
doi:10.1371/journal.pone.0037317.g002
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Tumorigenesis
Given the drastic effects of cdc42 deletion on cell proliferation
and anchorage-independent growth, it seems likely that Cdc42 loss
would impair the ability of HRasV12 to drive tumor formation.
Therefore, following Cdc42 deletion, cells were injected sub-
cutaneously into the flanks of immunocompromised nude mice.
Cdc42-deficiency resulted in a significant reduction in xenograft
tumor growth (Figure 4a). Tumors were isolated at the completion
of the study and tumors arising from Cdc42-proficient cells grew
significantly larger than Cdc42-deficient tumors and exhibited
general differences in tumor architecture (Figure 4b & 4c).
Interestingly, while genotyping on cells prior to injection into
mice seemed to reveal an efficient recombination of the cdc42
locus, PCR performed on DNA isolated from tumors revealed
a resurgence of the non-recombined locus in tumors arising from
Cdc42-deficient cells (Figure 4d). This suggests that residual
Cdc42-proficient cells remained following Cre-mediated cdc42
deletion and that those cells were selected for upon injection into
mice. It is possible that Cdc42-null cells might more easily
Figure 3. Loss of Cdc42 in HRasV12 transformed cells results in reduced cell proliferation and anchorage-independent growth. (a)
Equal cell numbers were plated following cdc42 deletion and cells were counted by trypan blue exclusion every three days for 9 days. Curves
represent at least two independent experiments performed in triplicate. (b) Cdc42-proficient and –deficient HRasV12 cells were grown in a 0.3%
agarose solution. Experiments were performed in triplicate and 9 independent fields were counted for colonies. (c) Exponentially growing cells were
pulsed with 5-bromodeoxyuridine (BrdU) for 1 hr. prior to harvest. Cells were stained with anti-BrdU and propidium iodide (PI) and analyzed by flow
cytometry. Graphs represent at least three independent experiments. (d) Cell lysates were immunoblotted for the cell cycle regulators, Cyclin D1 and
p16
ink4a. Gapdh served as a loading control.
doi:10.1371/journal.pone.0037317.g003
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the immune system; these results indicate that loss of Cdc42 in
oncogenic Ras transformed cells causes a growth disadvantage
in vivo as well as in vitro.
Cdc42 Status does not Affect the Growth or
Transformation of c-Myc-transformed Cells
While Ras-transformed cells are exquisitely sensitive to Cdc42
loss when compared to non-transformed control cells, whether
Cdc42 is also important for transformation mediated by oncogenes
of distinct pathways has not been addressed. c-Myc is another
potent and widely studied oncogene which, like Ras, has been
shown to cooperate with p53 loss to promote cellular trans-
formation [27]. Cells immortalized by dominant negative p53
were transformed through overexpression of c-Myc (Figure 5a).
Comparison of Cdc42 activation status between HRasV12 and c-
Myc transformation revealed a reduction in the levels of GTP-
bound Cdc42 in c-Myc transformed cells compared to HRasV12-
expressing cells (Figure 5b). Furthermore, upon Cre-mediated
cdc42 depletion, c-Myc transformed cells showed no difference in
cell morphology (Figure 5d), cell growth (Figure 5e) or anchorage-
independent growth (Figure 5f). While these data are not sufficient
to conclude that the deleterious effects of Cdc42 loss are exclusive
to Ras-transformed cells, they suggest that Cdc42 depletion is not
universally detrimental to transformed cells per se, as c-Myc
transformation is not dependent on Cdc42 function. Thus, the
Figure 4. Cdc42-deficiency impairs HRasV12-driven tumorigenesis. (a) Cdc42 proficient and deficient cells in a 1:1 PBS:matrigel mixture
were subcutaneously injected into the flanks of immunocompromised nude mice. Developing tumors were measured at indicated time points with
calipers to determine tumor volume. n=6. (b) 16 days post-injection mice were sacrificed and tumors excised and weighed (upper panel). A
representative image of tumors from three mice are shown (lower panel). (c) Tumors were fixed, sectioned and stained with hematoxylin and eosin.
(d) Left panel - The recombination status of the cdc42 locus was determined for cells prior to injection into nude mice by genomic PCR. Right panel -
DNA was isolated from resulting subcutaneous tumors and the recombination status of cdc42 determined by PCR. Tumors from two representative
mice were shown. The upper band corresponds to the non-recombined loxp/loxp allele from injected cells, the middle band corresponds to the wild-
type cdc42 allele derived from stromal cells derived from the recipient mouse, and the lower band corresponds to the recombined cdc42 allele.
doi:10.1371/journal.pone.0037317.g004
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on oncogenic context. Furthermore, it seems that relatively
elevated level of active Cdc42 may be predictive of a cells
sensitivity to Cdc42 loss, as the effect of Cdc42 deletion on non-
transformed and c-Myc transformed cells is minimal compared to
HRasV12-transformed cells which exhibit higher levels of GTP-
bound Cdc42 (see Figure 1c and 5b). Consistently, competitive
proliferation assays in which a 1:1 mix of Cdc42 proficient and
deficient cells were seeded together and passaged over time,
revealed a significant growth advantage of Cdc42 positive over
Cdc42 negative HRasV12 cells, while Cdc42 proficiency did not
provide a growth advantage for non-transformed or c-Myc
transformed cells (Figure S3).
Growth Defects Associated with Cdc42 Loss are Partially
Rescued by Active Akt
Since it appears that the loss of Cdc42 is selectively detrimental
to HRasV12-transformed cells, the effect of Cdc42 loss on known
Ras-effector pathways was examined. We had previously observed
that the deletion of Cdc42 in HRasV12-expressing cells results in
reduced p-PAK1 levels (Figure 2d), a protein known to regulate
activation and signaling through Raf-MEK-ERK [14,15]. There-
fore, we first examined the ability of Cdc42 loss to impinge upon
this pathway. Surprisingly, Cdc42 loss did not significantly alter p-
MEK or p-ERK levels (Figure S4); however, reproducible
reductions in p-Akt levels were observed (Figure 6a and S4),
suggesting that Cdc42 deficiency alters signaling through another
Ras effector pathway, PI3K-Akt. To assess the significance of
reduced Akt activation on the Cdc42 deficient phenotype,
a myristoylated, constitutively active Akt construct was transiently
expressed in Cdc42-deficient HRasV12 cells (Figure 6b). Cells
were subjected to BrdU pulse followed by BrdU and propidium
iodide staining. The expression of active Akt resulted in
a significant, but partial rescue of the cell proliferation defect
observed in Cdc42-deficient cells (Figure 6c). Consistently, myr-
Akt was able to partially rescue the G1 growth arrest observed
upon Cdc42 loss (Figure 6d). Therefore, while a reduction in Akt
signaling contributes to growth defects observed upon Cdc42 loss,
there are likely additional mechanisms at play. Alternatively, myr-
Akt expression may not result in reconstitution of all Akt functions.
Specifically, expression of myr-Akt results in constitutive Akt
localization at the cell surface where it is activated; however, Akt
has also been shown to have nuclear functions [28] which would
not be restored by such a mutant.
Cdc42 Deletion Inhibits HRasV12-driven Tumor Growth
While constitutive deletion of cdc42 inhibits tumor formation
and subsequent growth, to address the feasibility of targeting
Cdc42 for therapeutic intervention in tumors driven by HRasV12
mutation, cdc42 was inducibly deleted in established tumors.
HRasV12; Cdc42f/f cells were stably transduced with Cre-ER
T,
such that cdc42 could be conditionally deleted upon tamoxifen
administration (Figure 7a) resulting in a near complete reduction
of Cdc42 protein (Figure 7b). It is worth noting that the ER-Cre
allele is somewhat leaky, allowing for modest amounts of
recombination even in the absence of tamoxifen (Fig. 7A, 7E).
HrasV12; Cdc42f/f cells +/2 Cre-ER
T were injected into the
flanks of immunocompromised nude mice. Five days post-
injection, palpable tumors had formed, at which time, mice were
administered either 4-OH tamoxifen or vehicle control once daily,
five days a week for the duration of the study. While tamoxifen
treatment alone did not inhibit the growth of tumors lacking the
Cre-ER
T construct compared to vehicle controls, Cre-ER
T
positive tumor growth was significantly inhibited by tamoxifen
administration (Figure 7c). Furthermore, at the end of the assay,
tamoxifen-treated, Cre-ER
T positive tumors were significantly
smaller compared to controls (Figure 7d). Interestingly, while
tamoxifen treatment significantly enriched cdc42 recombination in
treated tumors, it was not able to induce complete deletion of the
gene (Figure 7e), further supporting the notion that Cdc42-
deficiency is counter-selected and functional Cdc42 signaling is
critical for Ras-driven tumorigenesis.
Discussion
Activated Cdc42 mutants are capable of transforming immor-
talized fibroblasts, suggesting a role for Cdc42 in oncogenesis [29].
While mutations in Cdc42 have not been reported in human
cancer, upregulation of Cdc42 protein expression or activity has
been reported in a variety of tumor types and in some instances
have been correlated with poor prognosis [30,31,32,33]. However,
how Cdc42 activity contributes to the transformed phenotype and
cooperates with other oncogenic events has not been rigorously
explored. Furthermore, additional studies are needed to assess the
consequences and feasibility of targeting Cdc42 signaling in
distinct tumorigenic and tumor maintenance contexts. Here, we
report that Cdc42 is critical for oncogenic Ras-driven cell
transformation and tumor growth. Consistent with studies using
dominant-negative Cdc42 mutants [17], we found that the loss of
Cdc42 dramatically inhibits the ability of HRasV12 to promote
cellular transformation, as determined by soft agar colony
formation. However, in contrast to dominant-negative studies,
we reveal that Cdc42 loss results in a significant reduction in cell
growth, attributable to a G1 phase cell cycle arrest. Interestingly,
this observation is consistent with a previous report that suggested
a requirement Cdc42 for progression into S phase by dominant
negative mutant expression [24]. The current work is significant
because it unambiguously demonstrates the essential role of Cdc42
activity in Ras-mediated transformation and tumorigenesis by
a genetic means, as previous approaches utilizing overexpression
of a mutant Cdc42 may very well introduce non-specific artifacts
due to cross-reactivity of dominant negative Cdc42 mutant with
multiple upstream Rho GEFs, thus affectingother Rho GTPases
and related signaling networks. In addition to studies carried out in
rodent cells, transformation of human fibroblasts with HRasV12 is
also inhibited upon dominant negative Cdc42 expression. In-
terestingly, expression of angiogenic factors was downregulated
upon Cdc42 inhibition in this model [34]. However, while this
effect may account for differences in tumorigenesis in vivo, it does
not explain in vitro changes in cell growth observed upon Cdc42
inhibition.
Interestingly, the level of Cdc42 activity was found to be
significantly enhanced upon HRasV12 expression compared to
non-transformed or c-Myc transformed cells, suggesting that
Cdc42 can be specifically activated by oncogenic Ras. Consistent
with the idea that oncogenic Ras signaling renders cells ‘‘addicted’’
to Cdc42 activation, HRasV12-transformed cells are exceedingly
sensitive to Cdc42 deletion, while non-transformed cells or cells
transformed by c-Myc overexpression are minimally affected by
Cdc42 loss. This further suggests that Cdc42 dependence is
restricted to certain oncogenic contexts, such as those induced
upon oncogenic H-Ras activation.
In addition to changes in cell growth, we observed a dramatic
change in the morphology of HRasV12-transformed cells upon
Cdc42 loss, which correlated with a reduction in the activation of
the focal adhesion protein, FAK. One recent study by Zheng et. al,
suggested that phosphorylation of FAK downstream of Ras is
inhibited to promote Ras-induced cell migration and that the
Genetic Evidence of Cdc42 in Ras Transformation
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37317Figure 5. Cdc42 loss does not impair transformation by the oncoprotein, c-Myc. (a) p53-immortalized cells were infected with a retrovirus
expressing the oncoprotein, c-Myc. c-Myc overexpression was verified by western blot analysis. (b) Pull-down assays were performed with GST-PAK1
to determine the relative abundance of activated Cdc42 in HRasV12 vs. c-Myc transformed cells. (c) Lysates from c-Myc transformed cells infected
with Ad-GFP or Ad-GFP-Cre were immunoblotted for Cdc42. (d) Cultured c-Myc transformed cells were visualized 4 days following cdc42 deletion by
bright field microscopy (upper 2 panels). Cells were fixed and stained with rhodamine-phalloidin and DAPI to visualize actin structures (lower 2
panels). (e) An equal number of c-Myc transformed Cdc42 proficient and deficient cells were seeded. Cells were counted every three days by trypan
blue exclusion. Curves represent at least two independent experiments performed in triplicate. (f) Cdc42-proficient and –deficient c-Myc cells were
grown in a 0.3% agarose solution. Experiments were performed in triplicate and 9 independent fields were counted for colonies. ns=not significant.
doi:10.1371/journal.pone.0037317.g005
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[11]. Interestingly, we also see a decrease in p-FAK levels
following Ras transformation (Fig. 2d); however p-FAK levels are
largely absent following Cdc42 deletion. This seeming discrepancy
could possibly reflect a dosing effect, as the previous study utilizes
an siRNA-mediated silencing of Cdc42, which often leaves
residual protein, while our targeted gene deletion approach
eliminates Cdc42 signaling to a point which is not conducive to
continued signaling to FAK. Alternatively, this could represent
a cell-type specific effect. However, it is worth noting that, while
the mechanism proposed by Zheng et al. for Cdc42-induced FAK
inhibition involved activation of ERK signaling downstream of
active Cdc42, we did not observe any appreciable disruption of
either MEK or ERK activation upon Cdc42 loss (Figure S4). This
observation is consistent with previous reports that demonstrated
activation of JNK signaling, but not ERK signaling, upon Cdc42
activation [24,35].
While changes in the phosphorylation status of MEK and ERK
were not observed in HRasV12-expressing cells following Cdc42
loss, reduction in the levels of p-Akt was evident, suggesting that
Cdc42 depletion may compromise the activation of PI3K signaling
downstream of activated Ras. This is consistent with reports that
GTP-bound Cdc42 can interact with the p85 subunit of PI3K to
modulate PI3K activity [13]. Recently, Ras was reported to
associate with Cdc42 at endomembranes, while Ras molecules
restricted to the plasma membrane were able to maintain signaling
to Raf [10]. It is tempting to hypothesize that Cdc42 may
modulate Ras-mediated transformation by altering signaling to
PI3K at endomembranes. However, complementing Cdc42
deficient cells with a constitutively active Akt was only able to
partially restore proliferation of Cdc42 deficient cells, indicating
that additional mechanism may exist by which disruption of
Cdc42 signaling hinders Ras-induced cell growth. Aside from
discrete signaling activities of Ras localized at various cellular
compartments, restriction of Ras localization also appears to
impact the ability of Ras to promote transformation [10,36,37].
To this end, whether Cdc42 loss impacts subcellular localization of
oncogenic Ras has not been explored. Interestingly, Cdc42 has
been previously shown to modulate EGFR-induced transforma-
tion by regulating its localization and turnover [38,39], establish-
ing a precedence for Cdc42-mediated changes in transformation
following modulation of oncogene localization and stability.
Figure 6. Growth defects observed in HRasV12-transformed cells following Cdc42 loss are partially rescued by activation of Akt
signaling. (a) Cell lysates from non-transformed and HRasV12-transformed cells were immunoblotted for phospho-Akt. Gapdh serves as a loading
control. (b) Cells were infected with Ad-GFP, Ad-GFP-Cre or Ad-GFP-Cre + Ad-myr-Akt. Cell lysates were obtained and blotted for Akt expression. (c)
Exponentially growing cells were pulsed with BrdU for 1 hour prior to harvest. Cells were stained with anti-BrdU and PI and analyzed by flow
cytometry. (d) PI staining was used to determine the percentage of cells with 2N DNA content. Graphs represent at least three independent
experiments.
doi:10.1371/journal.pone.0037317.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e37317Figure 7. Cdc42 deletion in HRasV12-driven tumors inhibits tumor growth. (a) HRasV12; Cdc42
f/f cells were transduced with retroviral ER-
Cre and selected with puromycin. Antibiotic resistant cells were pooled and treated in culture with 4-OH Tamoxifen (4-OHT) or vehicle.
Recombination at the cdc42 locus was determined by PCR. (b) Cell lysates were isolated from cells cultured in the presence and absence of 4-OHT.
Western blotting was performed to determine Cdc42 protein levels following Tamoxifen-induced recombination. (c) HRasV12; ER-Cre; Cdc42
f/f and
HRasV12; Cdc42
f/f cells were injected into the flanks of immunocompromised nude mice. Five days post-injection, palpable tumors had formed and
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e37317Understanding the signaling events necessary for the transform-
ing activities of Ras is crucial for the development of novel Ras-
targeted therapies. Emerging studies have begun to explore the
therapeutic values of various targeting strategies outside the
canonical Ras effector pathway, Raf-MEK-ERK, and emphasize
the significance of identifying additional pathways either directly
involved in Ras signaling or functioning as key modifiers that are
required for oncogenic Ras-driven tumorigenesis [5,8,9]. Whether
and how Cdc42 and its related pathways contribute to Ras-
mediated transformation and tumor maintenance in primary
human pathologies will be an issue of further investigation. In
particular, given the well appreciated cell-type specific signaling
function of Cdc42 [40], it can be anticipated that the proof of
principle shown here may apply to specific tissue/cell types where
Ras-induced transformation may be intimately dependent on
Cdc42. Additionally, while the described studies specifically
identify a requirement for Cdc42 in HRasV12-driven trans-
formation, how Cdc42 might affect transformation resulting from
the activation of other Ras proteins (i.e. KRAS and NRAS)
commonly activated in human cancers remains to be explored.
Materials and Methods
Ethics Statement
This study was carried out in accordance with recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the Cincinnati Children’s Hospital Research Foundation. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Cincinnati Children’s Hospital Research
Foundation (permit Number:8D06052). When necessary, CO2
euthanasia was used. This method was approved by the Animal
Care and Use Committee of the Cincinnati Children’s Hospital
Research Foundation and consistent with the recommendations of
the Panel on Euthanasia of the American Veterinary medical
Association.
Cell Lines
Primary mouse embryonic fibroblasts were isolated from
cdc42
f/f embryos at embryonic day 12.5 as described previously
(Guo JBC 2006). Immortalized cdc42
f/f fibroblasts were
generated through the transduction of cells with retrovirus
expressing dominant negative p53 (LXSN-p53dd) followed by
selection in 250 mg/ml G418. The dominant negative p53
construct was kindly provided by Moshe Oren of the Weizmann
Institute of Science. Immortalized cdc42
f/f fibroblasts were
transformed through retroviral transduction of either MIEG3-
HRasV12 or pKH3-c-Myc and infected cell populations were
obtained following fluorescence activated cell sorting (FACS) for
GFP 48 hours after infection. All cell lines were cultured in
DMEM containing 10% fetal bovine serum, 100 U/ml penicillin/
streptomycin and 2 mM L-glutamine and maintained at 37uC and
5% CO2.
Viral Transduction
Conditional cdc42 deletion was achieved following Ad-GFP-
Cre infection with Ad-GFP serving as a control. Adenoviral
transduction efficiency was monitored by GFP expression and was
determined to be .95%. For retroviral transductions, cells were
transduced overnight with 4 ml of retroviral-containing media
supplemented with 5 mg/ml of polybrene. Pure populations of
transduced cells were obtained following antibiotic selection or
FACS 48–72 hrs. post-transduction as indicated.
PCR
Recombination at the cdc42 locus was monitored by genomic
PCR. DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA)
was used to extract DNA from infected cells or tumor tissue.
Primer sequences: CDC42SA2F: AGA CAA AAC AAC AAG
GTC CAG AAA C CDC42LA1r: CTG CCA ACC ATG ACA
ACC TAA GTT C.
Immunoblot Analysis and Ras/Cdc42 Pull-down Assay
For immunoblot analysis, total cell lysates were resolved by
SDS-PAGE as previously described [41]. Specific proteins were
detected using the following primary antibodies: From Cell
Signaling Technology (Boston, MA, USA) - Cdc42, p-FAK(Tyr
397), p-MLC(Ser 19), MLC, p-GSK3b(Ser 9), GSK3b,p -
PAK1(Thr 423), PAK1, p-Akt(Ser 473), Akt, p-ERK1/2(Thr
202/Tyr 204), ERK1/2, p-MEK1/2(Ser 217/221), MEK,
cleaved caspase 3. From Santa Cruz Biotechnology (Santa Cruz,
CA, USA)- p16, c-Myc, HA. From BD Biosciences (Franklin
Lakes, NJ, USA)- Cdc42, p53. From Bethyl Laboratories
(Montgomery, TX, USA)- p-WASP(Ser 483/484). From Onco-
gene Research Products (La Jolla, CA,USA)- c-H-Ras. From
Fitzgerald (Acton, MA, USA)- Gapdh. From Thermo Fisher
Scientific (Fremont, CA, USA)- Cyclin D1.
For HRas and Cdc42 pull-down assays, GST- Cells were lysed
through direct addition of Lysis Buffer(20 mM Tris-HCl ph 7.6,
100 mM NaCl, 10 mM MgCl2, 1% Triton x-100, 0.2% SDS with
protease/phosphatase inhibitors) to the culture dish. 200–400 mg
of total cell lysate was incubated with 20 mg of glutathione-agarose
immobilized GST-fusion proteins (GST-Raf for HRas, GST-
PAK1 for Cdc42) for 45 minutes at 4uC. 10% of protein quantity
used for pull-down was retained for total input controls. Following
incubation, beads were washed three times with wash buffer and
bound proteins were resolved by SDS-PAGE and bound/active
proteins were detected by immunoblotting.
Immunofluorescence and TUNEL staining. Cells were
seeded on glass coverslips and fixed with 3.7% formaldehyde.
Fixed cells were stained with Rhodamine-phalloidin (Invitrogen,
Eugene, OR, USA) and 4,6-diamidino-2-phenylindole (DAPI)
(Invitrogen). TdT-mediated dUTP nick end (TUNEL) labeling
was carried out using In Situ Cell Death Detection Kit, TMR Red
(Roche, Indianapolis, IN, USA). Staining was carried out
according to manufacturer’s protocol.
Cell Growth Assay
2610
5 cells were seeded in 10 cm dishes in triplicate. Cells were
maintained at subconfluence and at days 3, 6, and 9 cells were
harvested and viable cells counted on a hemocytometer by trypan
blue exclusion.
mice were administered 100 ml of 10 mg/ml 4-OHT in sunflower seed oil or vehicle control once a day, five days a week for 3 weeks. Tumor volume
was monitored by caliper measurements. n=8. (d) At 25 days post-injection, mice were sacrificed and tumors excised and weighed. A representative
image of 4 HRasV12; ER-Cre; Cdc42f/f tumors treated with either tamoxifen or vehicle control is shown. (e) Genotyping was performed on DNA
isolated from HRasV12; ER-Cre; Cdc42
f/f tumors treated with either vehicle or 4-OHT to determine the status of the cdc42 locus. A representative
image of genotyping results from two mice per condition (two tumors per mouse) is shown. Densitometry was performed using imageJ software and
the intensity of the recombined cdc42 allele relative to the non-recombined cdc42 allele is plotted.
doi:10.1371/journal.pone.0037317.g007
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e37317Cell cycle analysis. Subconfluent cells were pulsed with
10 mg/ml BrdU prior to cell harvest and fixation with 100%
EtOH overnight at 4uC. Fixed cells were incubated for 30 min. at
37uC in 2N HCl containing 0.5 mg/ml pepsin. Following
incubation, acid was neutralized with 0.1M sodium tetraborate.
Cells were washed with phosphate buffered saline (PBS) containing
0.5% BSA and PBS +0.5% BSA +0.5% Tween20 before 1 hour
incubation with FITC-conjugated anti-BrdU (BD Pharmingen).
Stained cells were washed and resuspended in propidium iodide
with RNase A for flow cytometric analysis.
Soft Agar Colony Formation
20,000 cells were seeded per well in a six well dish. Cells were
mixed with 0.3% agarose in growth media and layered on top of
0.6% agarose in growth media. Colonies were counted under
a light microscope 2–3 weeks post-plating. For each experiment,
cells were seeded in triplicate and three fields per well were
quantified.
Xenograft Models
In vitro deletion- HRasV12-transformed cells were infected with
either Ad-GFP or Ad-GFP-Cre to obtain cdc42 deletion. 5610
5
infected cells were suspended in 200 ml of a 1:1 PBS:matrigel mix
and injected subcutaneously into the flanks of athymic nude mice.
Tumor growth was monitored by caliper measurements. Tumor
volume was calculated using the formula: volume=0.526
length6width
2. Tumors were excised from sacrificed mice at
indicated timepoint, weighed, and a portion of the tumors retained
for DNA extraction/genotyping, while the remaining tumor was
formalin-fixed and paraffin-embedded for sectioning. N=6.
In vivo deletion. 3610
5 HRasV12;Cdc42f/f which were
transduced with pBabe-Cre-ERT or control cells were sub-
cutaneously injected into the flanks of athymic nude mice. Five
days post-injection, palpable tumors had formed, at which time
100 ml injections of 10 mg/ml 4-OH Tamoxifen (Sigma-Aldrich)
in sunflower seed oil was administered daily, five days a week for 3
weeks. Tumor growth was monitored by measurement with
calipers. Following three weeks, mice were sacrificed, tumors
excised and weighed prior to harvest of tumor tissue for DNA
extraction and genotyping. N=8.
Supporting Information
Figure S1 Cdc42 deletion does not induce cell death. (a)
Following Cdc42 deletion, cells were fixed and TUNEL staining
was performed. (b) Following Cdc42 deletion, both adherent and
floating cells were harvested for immunoblotting for cleaved
caspase 3. Gapdh serves as a loading control.
(EPS)
Figure S2 Cdc42 overexpression in HRasV12 cells does
not increase proliferation, but enhances anchorage-
independent cell growth. (a) HRasV12-transformed cells
were retrovirally transduced with wild-type Cdc42 or vector
control. Cell lysates were blotted for Cdc42. (b) An Equal number
of Cdc42 overexpressing and vector control cells were plated on
day 0. Cells were counted every 3 days by trypan blue exclusion.
Experiment was performed in triplicate. (c) Vector control and
Cdc42-overexpressing cells were grown in 0.3% agarose. Colonies
were counted one week and three weeks after plating. Experiments
were performed in triplicate with 9 independent fields counted.
(EPS)
Figure S3 Cdc42 deficiency is selected against in
HRasV12 cells, but not c-Myc transformed or non-
transformed cell lines. Following Cdc42 deletion, an equal
number of Cdc42+ and Cdc422 cells were seeded. At confluency,
cells were passaged and a small number harvested for PCR to
assess the relative abundance of the loxp and recombined cdc42
alleles. Cultures were passaged a total of three times. Band
intensity was determined using imageJ software, and the
percentage of non-recombined to recombined cdc42 was plotted
relative to the initial seeding.
(EPS)
Figure S4 Cdc42 deficiency alters activation of Akt, but
not MEK-ERK signaling. Non-transformed and HRasV12
transformed cells were harvested for western blot analysis
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